Company Overview of HUYA Bioscience International, LLC
HUYA Bioscience International, LLC identifies and licenses pre-clinical and clinical stage compounds in China. It engages in accelerating the development of biopharmaceutical product opportunities originating in China. The company offers HBI-8000, a histone deacetylases inhibitors for cancer; HBI-3000, a multi-ion channel blocker for the treatment of arrhythmia; and HBI-3802, a small molecule for improving heart function, as well as stimulates cardiac stem cell differentiation into functional cardiomyocytes, and replaces and remodels dead myocardium with new functional tissues. HUYA Bioscience International, LLC has strategic alliances with China Wuqing Development Area and Korea Drug Develo...
12531 High Bluff Drive
San Diego, CA 92130
Founded in 2004
Key Executives for HUYA Bioscience International, LLC
Founder and Executive Chairman
Vice President of Finance
Senior Vice President of Operations
Chief Technology Officer and Chief Operating Officer of Asia
Head of Therapeutics China
Compensation as of Fiscal Year 2017.
HUYA Bioscience International, LLC Key Developments
HUYA Bioscience International Establishes Strategic Partnership with Suzhou BioTOP
Jul 10 17
HUYA Bioscience International announced a strategic collaboration agreement with Suzhou BioTOP Technical Service Co. Ltd. The collaboration will focus on promoting the development of biomedical innovations from companies and research organizations in Suzhou BioBay that help to meet the increasing demand to fill global pharmaceutical pipelines. The agreement combines the expertise of both HUYA and BioTOP to promote biomedical innovations with global market potential in the Yangtze River Delta region. Local pharmaceutical companies and research organizations in BioBay will have opportunities to access HUYA's international pharmaceutical knowledge and network resources, as well as the HUYA team's expertise in drug development and commercialization. In return, HUYA will have priority to evaluate certain research and development opportunities of these entities, and potentially co-develop them for global markets in the future. This partnership is an exciting strategic step given the knowledge sharing and synergies it will create between HUYA and BioTOP.
HUYA Bioscience International and CAS Innovation and Investment Company Establish Strategic Collaboration
Jan 18 17
HUYA Bioscience International announced a strategic collaboration agreement with the Chinese Academy of Sciences Innovation and Investment Company. The collaboration will focus on developing and commercializing biomedical innovations discovered by leading scientists at CAS to meet the medical needs of patients around the world. Under this agreement, HUYA and CAS Innovation will collaborate to develop novel drugs discovered by CAS scientists. Biotech and pharmaceutical R&D organizations within the CAS Innovation platform will have access to HUYA's international pharmaceutical expertise and networks as well as support from HUYA's global team of experts. In turn, HUYA will have priority to evaluate certain research and development projects conducted by these CAS organizations and secure partnerships to further develop and commercialize these candidate therapeutics for global markets.
HUYA Bioscience International, LLC Presents at BIO Europe 2016 Conference, Nov-08-2016 03:45 PM
Nov 5 16
HUYA Bioscience International, LLC Presents at BIO Europe 2016 Conference, Nov-08-2016 03:45 PM. Venue: KoelnMesse - Congress Center North, Cologne, Germany.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries